Adicet Bio Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 143

Employees

  • Stock Symbol
  • ACET

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $1.24
  • (As of Monday Closing)

Adicet Bio General Information

Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 131 Dartmouth Street
  • 3rd Floor
  • Boston, MA 02116
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adicet Bio Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.24 $1.21 $1.05 - $3.77 $101M 82.2M 1.27M -$2.94

Adicet Bio Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 54,275 (79,879) 122,129 512,923
Revenue 0 0 24,990 9,730
EBITDA (143,522) (146,511) (70,870) (60,501)
Net Income (139,793) (142,658) (69,790) (61,999)
Total Assets 293,095 207,295 330,690 338,938
Total Debt 20,036 20,924 21,023 20,944
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Adicet Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therap
Drug Discovery
Boston, MA
143 As of 2023
00000
00000000 00000

0000 0

ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
San Diego, CA
000 As of 0000
00000
00000000 00000

0000 0

oluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occae
0000000000000
Santa Monica, CA
0000 As of 0000
00000
000.00 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Adicet Bio Competitors (31)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fate Therapeutics Formerly VC-backed San Diego, CA 000 00000 00000000 00000
Kite Pharma Formerly VC-backed Santa Monica, CA 0000 00000 000000&0 00000
RAPT Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 000000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Ember Therapeutics Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
You’re viewing 5 of 31 competitors. Get the full list »

Adicet Bio Patents

Adicet Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230009275-A1 Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof Pending 03-Dec-2019 0000000000
US-10596165-B2 Combination therapies Inactive 12-Feb-2018 00000000000 000
US-20190247386-A1 Combination therapies Active 12-Feb-2018 00000000000
JP-6995145-B2 Antibodies capable of hla-restricted binding to hla-a2 / tyrd and their uses Active 14-Jun-2017 00000000000 0
US-11485785-B2 Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof Active 14-Jun-2017 C07K16/2833 00
To view Adicet Bio’s complete patent history, request access »

Adicet Bio Executive Team (16)

Name Title Board Seat Contact Info
Chen Schor President, Chief Executive Officer & Board Member
Nick Harvey Chief Financial Officer
Don Healey Ph.D Chief Technology Officer, Technology
Blake Aftab Ph.D Chief Scientific Officer
Nancy Boman Ph.D Chief Regulatory Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Adicet Bio Board Members (12)

Name Representing Role Since
Andrew Sinclair Ph.D Abingworth Board Member 000 0000
Aya Jakobovits Ph.D Adicet Bio Board Member 000 0000
Carl Gordon Ph.D OrbiMed Board Member 000 0000
Chen Schor Adicet Bio President, Chief Executive Officer & Board Member 000 0000
Florent Gros Novartis Venture Fund Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Adicet Bio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Adicet Bio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adicet Bio‘s full profile, request access.

Request a free trial

Adicet Bio Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
resTORbio 15-Sep-2020 0000000000 0000 Biotechnology 0000 0000
Applied Immune Technologies 27-Jan-2016 Merger/Acquisition Drug Discovery 000 00000
To view Adicet Bio’s complete acquisitions history, request access »

Adicet Bio ESG

Risk Overview

Risk Rating

Updated April, 01, 2023

26.61 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.0

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Adicet Bio’s complete esg history, request access »

Adicet Bio FAQs

  • When was Adicet Bio founded?

    Adicet Bio was founded in 2014.

  • Who is the CEO of Adicet Bio?

    Chen Schor is the CEO of Adicet Bio.

  • Where is Adicet Bio headquartered?

    Adicet Bio is headquartered in Boston, MA.

  • What is the size of Adicet Bio?

    Adicet Bio has 143 total employees.

  • What industry is Adicet Bio in?

    Adicet Bio’s primary industry is Drug Discovery.

  • Is Adicet Bio a private or public company?

    Adicet Bio is a Public company.

  • What is Adicet Bio’s stock symbol?

    The ticker symbol for Adicet Bio is ACET.

  • What is the current stock price of Adicet Bio?

    As of 15-Jul-2024 the stock price of Adicet Bio is $1.24.

  • What is the current market cap of Adicet Bio?

    The current market capitalization of Adicet Bio is $101M.

  • Who are Adicet Bio’s competitors?

    Fate Therapeutics, Kite Pharma, RAPT Therapeutics, NexImmune, and Ember Therapeutics are some of the 31 competitors of Adicet Bio.

  • What is Adicet Bio’s annual earnings per share (EPS)?

    Adicet Bio’s EPS for 12 months was -$2.94.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »